Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Status:
Terminated
Trial end date:
2016-11-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of the investigational
anticancer drug DCR-MYC. DCR-MYC is a novel synthetic double-stranded RNA in a stable lipid
particle suspension that targets the oncogene MYC. MYC oncogene activation is important to
the growth of many hematologic and solid tumor malignancies. In this study the Sponsor
proposes to study DCR-MYC and its ability to inhibit MYC and thereby inhibit cancer cell
growth.